Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 540

1.

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.

Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, Soriano V, Phiri P, Hall A, Brett-Smith H.

AIDS. 2008 Sep 12;22(14):1779-87. doi: 10.1097/QAD.0b013e32830b3ab5.

PMID:
18753861
2.

Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.

Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H.

J Gastroenterol Hepatol. 2008 Sep;23(9):1320-6. doi: 10.1111/j.1440-1746.2008.05455.x. Epub 2008 Jun 28.

PMID:
18554238
3.

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H.

Gastroenterology. 2007 Nov;133(5):1437-44. Epub 2007 Aug 14.

PMID:
17983800
4.

[Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].

Ma H, Ren JB, Li HY, Wang Y, Wang RL, Liang L, Sun SJ, Jia JD.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007 Jun;21(2):102-4. Chinese.

PMID:
17653304
5.

[Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area].

LI H, WANG ZY, ZHANG DZ, SHI XF, ZHOU Z, REN H.

Zhonghua Gan Zang Bing Za Zhi. 2009 May;17(5):338-41. Chinese.

PMID:
19497197
6.

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.

Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes RG; BEHoLD Study Group.

Gastroenterology. 2005 Oct;129(4):1198-209.

PMID:
16230074
7.

Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.

Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R; AI463026 BEHoLD Study Group.

Gastroenterology. 2006 Jun;130(7):2039-49.

PMID:
16762627
8.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group.

N Engl J Med. 2006 Mar 9;354(10):1011-20. Erratum in: N Engl J Med. 2006 Apr 27;354(17):1863.

9.

Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.

Miailhes P, Trabaud MA, Pradat P, Lebouché B, Chevallier M, Chevallier P, Zoulim F, Trepo C.

Clin Infect Dis. 2007 Sep 1;45(5):624-32. Epub 2007 Jul 30.

PMID:
17682999
10.

Entecavir for the treatment of chronic hepatitis B virus infection.

Matthews SJ.

Clin Ther. 2006 Feb;28(2):184-203. Review.

PMID:
16678641
11.

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group.

N Engl J Med. 2006 Mar 9;354(10):1001-10.

12.

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D.

Gastroenterology. 2002 Dec;123(6):1831-8.

PMID:
12454840
13.

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.

Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK; 903 Study Team; 907 Study Team.

J Infect Dis. 2004 Apr 1;189(7):1185-92. Epub 2004 Mar 12.

PMID:
15031786
14.

Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection.

Fang CT, Chen PJ, Chen MY, Hung CC, Chang SC, Chang AL, Chen DS.

J Hepatol. 2003 Dec;39(6):1028-35.

PMID:
14642622
15.
16.

[Investigation of entecavir medication of chronic hepatitis B patients in the Chongqing area who failed lamivudine treatment].

Wang ZY, Zhang DZ, Shi XF, Zhou Z, Ren H.

Zhonghua Gan Zang Bing Za Zhi. 2007 Jan;15(1):13-5. Chinese.

PMID:
17244451
17.

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R.

J Viral Hepat. 2010 Jan;17(1):16-22. doi: 10.1111/j.1365-2893.2009.01146.x. Epub 2009 Jul 19.

PMID:
19622117
18.

Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.

Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S.

AIDS. 2006 Oct 3;20(15):1951-4.

PMID:
16988516
19.

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.

Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group.

Hepatology. 2008 Jul;48(1):99-108. doi: 10.1002/hep.22323.

PMID:
18537189
20.

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, Gadano A, Lee Y, Mazzotta F, Thomas N, DeHertogh D.

Hepatology. 2001 Sep;34(3):578-82.

PMID:
11526545

Supplemental Content

Support Center